The Cicada Variant: What You Need to Know About the 2026 COVID Surge

As of late March 2026, the global health landscape is closely watching a new subvariant of SARS-CoV-2: the BA.3.2, more commonly known by its evocative nickname, the “Cicada” variant.

If you’re wondering whether this is another social media rumor or a genuine public health development, here is a high-quality, professional breakdown of what we know, why it’s trending, and the current CDC status.

What is the Cicada Variant (BA.3.2)?

The Cicada variant is a descendant of the BA.3 Omicron lineage. While BA.3 first appeared in late 2021, it quickly faded into the background.

The name “Cicada” was informally coined by researchers because of the variant’s unusual behavior. Much like the periodic cicada insects that remain underground for years before suddenly emerging in massive numbers, this lineage went virtually undetected for nearly two years before resurfacing with a massive suite of new mutations.

Key Facts at a Glance:

• Scientific Name: BA.3.2

• First Identified: November 2024 (South Africa)

• Status: Classified by the WHO as a “Variant Under Monitoring” as of December 2025.

• Presence: Detected in over 23 countries and at least 25 U.S. states (primarily through wastewater surveillance).

Why Scientists are Concerned: The “Hyper-Mutated” Profile

What sets the Cicada variant apart isn’t its current spread—which remains relatively low in the U.S. compared to the dominant XFG strain—but its genetic makeup.

• 70–75 Mutations: The variant carries an unusually high number of mutations in the spike protein. This is roughly double the amount seen in previous dominant strains like JN.1.

• Immune Escape: Because the spike protein is the primary target for vaccines and natural antibodies, such high divergence suggests the virus may be better at “slipping past” existing immune defenses.

• Evolutionary “Stealth”: Its ability to evolve quietly in the background for over a year suggests it may have been circulating in a specific population or animal reservoir before “re-emerging” into the global surveillance net.

Symptoms: The 2026 Checklist

Despite its significant genetic changes, clinical reports from March 2026 suggest that Cicada doesn’t present “new” or radical symptoms. It still largely behaves like a respiratory infection, though one specific symptom is being reported with higher frequency.

Common Symptoms:

• “Razorblade” Sore Throat: A hallmark of this variant is an exceptionally painful sore throat.

• Gastrointestinal Issues: Higher instances of nausea and diarrhea compared to previous 2025 strains.

• Standard Respiratory Signs: Fever, chills, persistent cough, and congestion.

• Neurological/Physical: Fatigue, headache, and muscle pain.

Note on Severity: As of March 29, 2026, there is no evidence that BA.3.2 causes more severe disease or higher rates of hospitalization than previous Omicron versions.

Travel and Prevention: CDC Recommendations

For those traveling in the spring of 2026, the CDC has updated its guidance to reflect the spread of BA.3.2, particularly in Northern Europe (Denmark, Germany, and the Netherlands) where it accounts for nearly 30% of cases.

CDC Traveler’s Checklist:

• Vigilant Testing: Travel with rapid antigen tests, especially if you are high-risk.

• Ventilation is Key: Prioritize outdoor activities or well-ventilated indoor spaces.

• Vaccination: The 2025–2026 booster remains the best defense against severe outcomes, even if its “match” for Cicada is slightly weaker.

• Masking: Consider a high-quality mask (N95/KN95) in crowded transit hubs or planes.

Comparison Table: Cicada vs. Previous Strains

The Bottom Line

The Cicada variant is a reminder that the virus is still finding creative ways to persist. While it is a “Variant Under Monitoring” due to its high mutation count, it is not currently a cause for panic. For most people, it remains a manageable respiratory illness.

This video provides a brief update from health officials on the emergence and monitoring of the variant in the United States.